1. Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis
- Author
-
Jin Suminokura, Morikazu Miyamoto, Tomoyuki Yoshikawa, Hiroko Kouta, Yoshihiro Kikuchi, Taira Hada, Hiroki Ishibashi, Tsubasa Ito, Hideki Iwahashi, Soichiro Kakimoto, Rie Suzuki, Hiroko Matsuura, Naohisa Kishimoto, and Masashi Takano
- Subjects
Ovarian carcinoma ,Bevacizumab ,Administration ,Prognosis ,Adverse effect ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Bevacizumab (Bev) plays the central role of the adjuvant therapy for patients with ovarian carcinoma. The aim of our study was to examine whether differences in the administration of Bev influence the prognosis of patients. Methods Patients with ovarian carcinoma who received treatment at two hospitals between 1999 and 2020 were identified. Patients treated with weekly low-dose administration of Bev (100 mg Bev on days 1 and 8 and 200 mg Bev on day 15, monthly) at one hospital (group A) and those with monthly high-dose administration of Bev (15 mg/kg of Bev on day 1, monthly) at another hospital (group B) were retrospectively compared. Results Among the total patients, 44 were assigned to group A and 33 were assigned to group B. More patients in group A had advanced disease (p = 0.03) and a lower dose of Bev at the first time during the first cycle administration (p
- Published
- 2022
- Full Text
- View/download PDF